IL266087B2 - Use of itolizumab to reduce phosphorylation of cd6 - Google Patents

Use of itolizumab to reduce phosphorylation of cd6

Info

Publication number
IL266087B2
IL266087B2 IL266087A IL26608719A IL266087B2 IL 266087 B2 IL266087 B2 IL 266087B2 IL 266087 A IL266087 A IL 266087A IL 26608719 A IL26608719 A IL 26608719A IL 266087 B2 IL266087 B2 IL 266087B2
Authority
IL
Israel
Prior art keywords
alcam
antibody
itolizumab
phosphorylation
complex
Prior art date
Application number
IL266087A
Other languages
English (en)
Hebrew (he)
Other versions
IL266087B1 (en
IL266087A (en
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of IL266087A publication Critical patent/IL266087A/en
Publication of IL266087B1 publication Critical patent/IL266087B1/en
Publication of IL266087B2 publication Critical patent/IL266087B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Electrically Operated Instructional Devices (AREA)
IL266087A 2016-10-18 2017-10-16 Use of itolizumab to reduce phosphorylation of cd6 IL266087B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641035602 2016-10-18
PCT/IB2017/056403 WO2018073721A1 (en) 2016-10-18 2017-10-16 Use of itolizumab to reduce phosphorylation of cd6

Publications (3)

Publication Number Publication Date
IL266087A IL266087A (en) 2019-06-30
IL266087B1 IL266087B1 (en) 2023-10-01
IL266087B2 true IL266087B2 (en) 2024-02-01

Family

ID=62019244

Family Applications (1)

Application Number Title Priority Date Filing Date
IL266087A IL266087B2 (en) 2016-10-18 2017-10-16 Use of itolizumab to reduce phosphorylation of cd6

Country Status (8)

Country Link
US (2) US20190248913A1 (cg-RX-API-DMAC10.html)
EP (1) EP3528846A4 (cg-RX-API-DMAC10.html)
JP (1) JP7065085B2 (cg-RX-API-DMAC10.html)
KR (1) KR102469798B1 (cg-RX-API-DMAC10.html)
AU (1) AU2017345390B2 (cg-RX-API-DMAC10.html)
CA (1) CA3076861A1 (cg-RX-API-DMAC10.html)
IL (1) IL266087B2 (cg-RX-API-DMAC10.html)
WO (1) WO2018073721A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
WO2019169015A1 (en) * 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
US20230076643A1 (en) * 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113083A1 (en) * 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
WO2015011658A1 (en) * 2013-07-23 2015-01-29 Biocon Limited Use of a cd6 binding partner and method based thereon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102514528B1 (ko) * 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113083A1 (en) * 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
WO2015011658A1 (en) * 2013-07-23 2015-01-29 Biocon Limited Use of a cd6 binding partner and method based thereon

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A IRA ET AL.,, IMMUNOLOGICAL AND HISTOLOGICAL EVALUATION OF CLINICAL SAMPLES FROM PSORIASIS PATIENTS TREATED WITH ANTI- CD 6 ITOLIZUMAB, 1 May 2014 (2014-05-01) *
HASSAN ET AL.,, CD 6 REGULATES T- CELL RESPONSES THROUGH ACTIVATION-DEPENDENT RECRUITMENT OF THE POSITIVE REGULATOR SLP-76, 1 September 2006 (2006-09-01) *
NAIR P ET AL,, CD6 SYNERGISTIC CO-STIMULATION PROMOTING PROINFLAMMATORY RESPONSE IS MODULATED WITHOUT INTERFERING WITH THE ACTIVATED LEUCOCYTE CELL ADHESION MOLECULE INTERACTION, 19 August 2010 (2010-08-19) *
RONCAGALLI ET AL.,, QUANTITATIVE PROTEOMIC ANALYSIS OF SIGNALOSOME DYNAMICS IN PRIMARY T CELLS IDENTIFIES THE CD 6 SURFACE RECEPTOR AS A LAT-INDEPENDENT TCR SIGNALING HUB, 2 March 2014 (2014-03-02) *

Also Published As

Publication number Publication date
KR102469798B1 (ko) 2022-11-22
KR20190070957A (ko) 2019-06-21
EP3528846A1 (en) 2019-08-28
EP3528846A4 (en) 2020-06-03
US20190248913A1 (en) 2019-08-15
WO2018073721A1 (en) 2018-04-26
AU2017345390A1 (en) 2019-05-02
IL266087B1 (en) 2023-10-01
US20240101700A1 (en) 2024-03-28
JP2020504597A (ja) 2020-02-13
AU2017345390B2 (en) 2024-08-08
JP7065085B2 (ja) 2022-05-11
IL266087A (en) 2019-06-30
CA3076861A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
US20240101700A1 (en) Use of itolizumab to reduce phosphorylation of cd6
US20220193199A1 (en) Il-15 and il-15ralpha sushi domain based modulokines
JP7565678B2 (ja) 組合せ医薬組成物
Bloemendaal et al. Anti–tumor necrosis factor with a glyco-engineered Fc-region has increased efficacy in mice with colitis
KR20200034958A (ko) 암 요법에서 면역 관련된 유해 사례를 치료하기 위한 가용성 cd24의 사용 방법
US20220227880A1 (en) Monoclonal antibody and a method of use for the treatment of lupus
HK40074884A (en) Il-15 and il-15ralpha sushi domain based on modulokines
HK40102087A (en) Il-15 and il-15ralpha sushi domain based on modulokines
HK40074884B (en) Il-15 and il-15ralpha sushi domain based on modulokines
HK40004449A (en) Il-15 and il-15raplha sushi domain based modulokines
HK40004449B (en) Il-15 and il-15ralpha sushi domain based modulokines